Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based
regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer
.